Loading clinical trials...
Loading clinical trials...
Patient Characteristics and Treatment Modalities in COPD Patients Assessed by GOLD2016 : a Cross-Sectional Study in China
Conditions
Locations
8
China
GSK Investigational Site
Xiamen, Fujian, China
GSK Investigational Site
Guangzhou, Guangdong, China
GSK Investigational Site
Changsha, Hunan, China
GSK Investigational Site
Hohhot, Inner Mongolia, China
GSK Investigational Site
Chengdu, Sichuan, China
GSK Investigational Site
Beijing, China
Start Date
May 31, 2017
Primary Completion Date
December 31, 2018
Completion Date
December 31, 2018
Last Updated
June 28, 2019
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions